Erratum: MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma (Modern Pathology (2012) DOI; 10.1038/modpathol.2012.149);MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma

Modern Pathology

Volumn 26, Issue 2, 2013, Pages 171-181

  Monsálvez, Veronica ^a   Montes Moreno, Santiago ^b   Artiga, María J ^c   Rodríguez, Maria E ^b   Espiridión, Beatriz S ^b   Lozano, Maria ^b   Fernández De Misa, Ricardo ^d   Rodríguez Peralto, Jose L ^a   Piris, Miguel A ^b   Ortíz Romero, Pablo L ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c Structural Biology and Biocomputing Programme   (Spain)

^d HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

Author keywords

cutaneous B cell lymphoma; miRNAs; prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; FORMALDEHYDE; MICRORNA; MICRORNA 150; MICRORNA 155; PARAFFIN; RITUXIMAB; RNA; SMALL UNTRANSLATED RNA; STEROID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER TISSUE; CONTROLLED STUDY; CUTANEOUS MARGINAL ZONE B CELL LYMPHOMA; CUTANEOUS MARGINAL ZONE LYMPHOMA; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; EMBEDDING; FEMALE; FOLLICULAR LYMPHOMA; GENE EXPRESSION; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MARGINAL ZONE LYMPHOMA; PATHOPHYSIOLOGY; PRIMARY CUTANEOUS B CELL LYMPHOMA; PRIMARY CUTANEOUS CENTROFOLLICULAR LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; RISK FACTOR; RNA EXTRACTION; TISSUE SECTION;

EID: 84873413392     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.209     Document Type: Erratum

References (52)

1. de Leval L, Harris NL, Longtine J, et al. Cutaneous b-cell lymphomas of follicular and marginal zone types: use of Bcl-6, CD10, Bcl-2, and CD21 in differential diagnosis and classification. Am J Surg Pathol 2001;25:732-741.
2. Hoefnagel JJ, Vermeer MH, Jansen PM, et al. Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance. Br J Dermatol 2003;149:1183-1191.
3. Hoefnagel JJ, Dijkman R, Basso K, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood 2005;105: 3671-3678.
4. Cerroni L, Volkenandt M, Rieger E, et al. bcl-2 protein expression and correlation with the interchromosomal 14;18 translocation in cutaneous lymphomas and pseudo-lymphomas. J Invest Dermatol 1994;102:231-235.
5. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-511.
6. Cerroni L, Arzberger E, Putz B, et al. Primary cutaneous follicle center cell lymphoma with follicular growth pattern. Blood 2000;95:3922-3928.
7. Geelen FA, Vermeer MH, Meijer CJ, et al. Bcl-2 protein expression in primary cutaneous large B-cell lymphoma is site-related. J Clin Oncol 1998;16: 2080-2085.
8. Goodlad JR, Krajewski AS, Batstone PJ, et al. Primary cutaneous follicular lymphoma: a clinicopathologic and molecular study of 16 cases in support of a distinct entity. Am J Surg Pathol 2002;26:733-741.
9. Senff NJ, Noordijk EM, Kim YH, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 2008;112:1600-1609.
10. Smith BD, Smith GL, Cooper DL, et al. The cutaneous B-cell lymphoma prognostic index: a novel prognostic index derived from a population-based registry. J Clin Oncol 2005;23:3390-3395.
11. Golling P, Cozzio A, Dummer R, et al. Primary cutaneous B-cell lymphomas-clinicopathological, prognostic and therapeutic characterisation of 54 cases according to the WHO-EORTC classification and the ISCL/EORTC TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome. Leuk Lymphoma 2008;49: 1094-1103.
12. Gerami P, Wickless SC, Rosen S, et al. Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome in primary cutaneous marginal zone lymphoma. J Am Acad Dermatol 2008;59:245-254.
13. Kodama K, Massone C, Chott A, et al. Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood 2005;106:2491-2497.
14. Mian M, Marcheselli L, Luminari S, et al. CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11). Ann Hematol 2010;90:401-408.
15. Zhang B, Pan X, Cobb GP, et al. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007;302:1-12.
16. Hammond SM. RNAi, microRNAs, and human disease. Cancer Chemother Pharmacol 2006;58 (Suppl 1):s63-s68.
17. Paranjape T, Slack FJ, Weidhaas JB. MicroRNAs: tools for cancer diagnostics. Gut 2009;58:1546-1554.
18. Jima DD, Zhang J, Jacobs C, et al. Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel micro-RNAs. Blood 2010;116:e118-127.
19. Malumbres R, Sarosiek KA, Cubedo E, et al. Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood 2009;113:3754-3764.
20. Zhang J, Jima DD, Jacobs C, et al. Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood 2009;113:4586-4594.
21. Xiao C, Calado DP, Galler G, et al. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 2007;131:146-159.
22. Eis PS, Tam W, Sun L, et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 2005;102:3627-3632.
23. Metzler M, Wilda M, Busch K, et al. High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes Chromosomes Cancer 2004;39:167-169.
24. Kluiver J, Poppema S, de Jong D, et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol 2005;207:243-249.
25. Montes-Moreno S, Martinez N, Sanchez-Espiridion B, et al. miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. Blood 2011;118:1034-1040.
26. Willenze R, Swerdlow SH, Harris NL, Verqier B. Primary cutaneous follicle centre lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds). WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues; 4th edn, IARC: Lyon, France, 2008, pp 227-228.
27. Davoren PA, McNeill RE, Lowery AJ, et al. Identification of suitable endogenous control genes for micro-RNA gene expression analysis in human breast cancer. BMC Mol Biol 2008;9:76.
28. Morrissey ER, Diaz-Uriarte R. Pomelo II: finding differentially expressed genes. Nucleic Acids Res 2009;37:W581-W586.
29. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586.
30. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976;34:585-612.
31. Senff NJ, Willemze R. The applicability and prognostic value of the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: results on a large cohort of primary cutaneous B-cell lymphomas and comparison with the system used by the Dutch Cutaneous Lymphoma Group. Br J Dermatol 2007;157:1205-1211.
32. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005;435:828-833.
33. Lawrie CH, Saunders NJ, Soneji S, et al. MicroRNA expression in lymphocyte development and malignancy. Leukemia 2008;22:1440-1446.
34. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65:7065-7070.
35. van der Fits L, van Kester MS, Qin Y, et al. MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sezary syndrome. J Invest Dermatol 2011;131:762-768.
36. Ballabio E, Mitchell T, van Kester MS, et al. MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. Blood 2010;116: 1105-1113.
37. van Kester MS, Ballabio E, Benner MF, et al. miRNA expression profiling of mycosis fungoides. Mol Oncol 2011;5:273-280.
38. Zhou B, Wang S, Mayr C, et al. miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl Acad Sci USA 2007;104:7080-7085.
39. Lawrie CH, Shilling R, Troussard X, et al. Expression profiling of persistent polyclonal B-cell lymphocytosis suggests constitutive expression of the AP-1 transcription complex and downregulation of Fas-apoptotic and TGFbeta signalling pathways. Leukemia 2009;23: 581-583.
40. Landgraf P, Rusu M, Sheridan R, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007;129:1401-1414.
41. Lawrie CH. MicroRNA expression in lymphoid malignancies: new hope for diagnosis and therapy? J Cell Mol Med 2008;12:1432-1444.
42. Lawrie CH, Chi J, Taylor S, et al. Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med 2009;13:1248-1260.
43. Yin Q, Wang X, McBride J, et al. B-cell receptor activation induces BIC/miR-155 expression through a conserved AP-1 element. J Biol Chem 2008;283: 2654-2662.
44. Vigorito E, Perks KL, Abreu-Goodger C, et al. MicroRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity 2007;27:847-859.
45. Thai TH, Calado DP, Casola S, et al. Regulation of the germinal center response by microRNA-155. Science 2007;316:604-608.
46. Dorsett Y, McBride KM, Jankovic M, et al. Micro-RNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation. Immunity 2008;28:630-638.
47. Teng G HP, Landgraff P, Rice A, et al. Micro-RNA-155 is a negative regulator of activation-induced cytidine deaminase. Immunity 2008;28:621-629.
48. de Yebenes VG, Belver L, Pisano DG, et al. miR-181b negatively regulates activation-induced cytidine deaminase in B cells. J Exp Med 2008;205:2199-2206.
49. Jung I, Aguiar RC. MicroRNA-155 expression and outcome in diffuse large B-cell lymphomaBr J Haematol 2009;144:138-140.
50. Roehle A, Hoefig KP, Repsilber D, et al. MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. Br J Haematol 2008; 142:732-744.
51. Desiderio S. Along came a spider: AID escapes a microRNA web. Immunity 2008;28:596-598.
52. Gottwein E, Mukherjee N, Sachse C, et al. A viral microRNA functions as an orthologue of cellular miR-155. Nature 2007;450:1096-1099.